SHERIDAN, WYOMING – November 7, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game.

The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.  

"We knew as a leader in diagnostics and testing we had to do something powerful to draw in donors," said Abbott Chairman and CEO Robert Ford. "What better way to inspire people to donate than tapping into rivalries between Big Ten schools and offering up a friendly competition.”

SHERIDAN, WYOMING – November 7, 2024 – The world of marathon running has expanded with the addition of the TCS Sydney Marathon presented by Asics to the Abbott World Marathon Majors (AWMM). Starting in 2025, Sydney will join the prestigious ranks of Tokyo, Boston, London, Berlin, Chicago, and New York in hosting one of the world's most renowned marathons.

This exciting development not only adds a new race to the AWMM series but also brings the Southern Hemisphere into the fold, offering runners a unique opportunity to compete in a world-class marathon in a stunning location. The inaugural Sydney Marathon as part of the AWMM is scheduled for August 31, 2025, and anticipation is already building.

"We cannot wait to see our community embrace this race and start planning their visits to run the streets of one of the finest cities in the world,” said AWMM CEO Dawna Stone. "Runners, your Sydney star awaits.”

SHERIDAN, WYOMING – November 7, 2024 – Abbott (NYSE: ABT) today announced significant strides in its pulsed field ablation (PFA) solutions within the electrophysiology field. The company has achieved key milestones, including the early completion of enrollment in the VOLT-AF IDE Study for the Volt™ PFA System and the initiation of the FOCALFLEX trial to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), designed for treating paroxysmal atrial fibrillation. These advancements underscore Abbott's commitment to providing innovative solutions for abnormal heart rhythms like atrial fibrillation (AFib).

In addition, Abbott has received U.S. Food and Drug Administration (FDA) clearance for the Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, further enhancing cardiac mapping capabilities for both PFA and radiofrequency (RF) ablation procedures.

SHERIDAN, WYOMING – November 7, 2024 – GE HealthCare, a leading global medical technology and diagnostics company, is poised to announce its latest quarterly earnings before the market opens on Wednesday. Financial analysts are predicting an increase in both revenue and profits compared to the same period last year, signaling continued resilience amidst a challenging global economic landscape.

This positive outlook follows a cautious adjustment made by the company in the previous quarter. Citing economic difficulties in China, GE HealthCare revised its full-year revenue growth projections downwards. However, the anticipated strong performance in the current quarter suggests that the company is effectively navigating these challenges and capitalizing on growth opportunities in other markets.

SHERIDAN, WYOMING – November 7, 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) has opened its new Pharma Research and Early Development Center (pRED) at its global headquarters in Basel. The center has 1,800 laboratory and office workplaces, bringing together researchers from different disciplines, explains Roche in a statement. The center’s inauguration was attended by Federal Councillor Guy Parmelin, Head of the Federal Department of Economic Affairs, Education and Research.

“The new pRED Center will play an integral role in collaborating with our research centers across the globe, aiming to boost the effectiveness and efficiency of our R&D, and to deliver the greatest impact for patients,” Thomas Schinecker, CEO of the Roche Group, is quoted as saying.

Further investments in the billions to follow

SHERIDAN, WYOMING – November 7, 2024 – Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present a robust body of data at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.  With more than 40 abstracts spanning nine blood disorders, Roche's presence at ASH underscores its unwavering dedication to improving outcomes for individuals battling lymphoma.

The company will unveil significant findings from studies evaluating its innovative lymphoma treatments, including Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab), and Columvi® (glofitamab), along with exciting new investigational combination data.

Key Highlights from Roche's ASH 2024 Presentations:

SHERIDAN, WYOMING – November 7, 2024 – Roche, a global healthcare pioneer, has announced continued strong sales growth in the third quarter of 2024. The company's performance was driven by high demand for both its Pharmaceuticals and Diagnostics divisions, with Group sales increasing by 9% at constant exchange rates (CER). [cite: 1, 2, 3]

“Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients’ lives around the world,” said Roche CEO Thomas Schinecker.

Pharmaceuticals Division

The Pharmaceuticals Division posted sales growth of 7% in the first nine months of 2024, with the base business (excluding COVID-19 products) growing by 9%. [cite: 3, 4, 5] This strong performance was fueled by continued high demand for newer medicines, including Vabysmo (serious eye diseases), Phesgo (breast cancer), and Ocrevus (multiple sclerosis).

SHERIDAN, WYOMING – November 7, 2024 –  Alpine Endurance Team has wrapped up its 2024 FIA World Endurance Championship campaign, marking the end of a learning year for its A424 Hypercar. The team secured a fourth-place finish in the 8 Hours of Bahrain, a race marked by intense competition. This result solidified their fourth-place standing in the World Endurance Manufacturers' Championship.

While the 2024 season has concluded, Alpine is already shifting its focus to the challenges and opportunities of 2025.  This forward-looking approach includes participation in the Rookies Tests this Sunday, with Jules Gounon and Victor Martins taking the wheel. This initiative highlights Alpine's commitment to developing young talent and preparing for future racing endeavors.

SHERIDAN, WYOMING – November 7, 2024 – World Bicycle Relief, a global non-profit organization dedicated to providing access to transportation in developing countries, has announced that Giant Group, the parent company of Giant, Liv, Momentum, and CADEX, will receive the 2024 Trailblazer Award. This prestigious award recognizes organizations and individuals who have made significant contributions to improving lives through transportation.

Giant Group has been a crucial partner of World Bicycle Relief for over 15 years, playing a key role in the design and manufacturing of the Buffalo Bicycle. This specially designed bike is built to withstand the challenging conditions in rural areas, providing reliable transportation for people in need.

SHERIDAN, WYOMING – November 6, 2024 – Team Peugeot TotalEnergies concluded their FIA World Endurance Championship season with a hard-fought podium finish in Bahrain, demonstrating resilience and a strong race strategy despite a challenging start to the year.

The team's #93 PEUGEOT 9X8, driven by Nico Müller and Mikkel Jensen, secured a third-place finish after starting at the back of the grid due to cancelled qualifying times. This impressive comeback showcased the car's pace and the team's strategic prowess.

"It was a hard race but we managed to secure a superb result in the end," said Nico Müller. "We started at the back of the grid because our qualifying times were cancelled, but we managed to produce a stunning comeback to finish on the podium!"